Skip to main content
. 2021 Sep 7;13(9):1784. doi: 10.3390/v13091784

Table 3.

List of compounds targeting non-viral proteins and proposed mechanism of action.

Compound Proposed Mechanism Clinical Trials Register Reference
Lactoferrin Sulfated glucosaminoglycan (sGAG) blocker NCT01677702 (nrp); NCT01092039 (nrp) [131,132,133,134,135]
Nanoparticles Heparan sulfate proteoglycans mimetic
Virion aggregation
- [23]
PDS fibrils Virion entrapment [25]
Carrageenans Virion entrapment NCT01944631 (cwr); NCT04533906 (nrp) [136,137]
LEI110 (*) PLA2G16 inhibitor - [117]
Geldanamycin HSP90 inhibitor - [119,138]
Pochonin D HSP90 inhibitor - [122]
Wortmannin PI 3-kinase inhibition - [139]
Dynasore Dynamin GTPase inhibitor - [140]
Blebbistatin Myosin ATPase activity inhibitor - [140]
Chlorpromazine Prevent the assembly/disassembly of clathrin lattices - [140]
Filipin Cholesterol sequestering - [140]
Itraconazole Oxysterol binding protein inhibitor - [141]
Monensin Endosome acidification inhibitor - [142]
Niclosamide Endosome acidification inhibitor - [143]
EIPA Endosome acidification inhibitor - [144]
Bafilomycin A Endosome acidification inhibitor - [145]
Ammonium Chloride Endosome acidification inhibitor - [146]
Cytochalasin D (CytD) Actin-polymerisation inhibitor - [145]
Budesonide Autophagy activator - [147]
DDD85646 N-myristoyltransferase inhibitor - [124]
ML-9 Myosin light chain kinase inhibitor - [148]
sMBP-V33333 Receptor mimetic - [149]
sICAM-1 Receptor mimetic - [150,151,152]
Dendrimers Blocking receptor attachment of EV-A71 and HIV - [24,153]
Deoxyglucose Metabolism modifier - [154]
Azithromycin Immunomodulatory - [155]
LL-37 Cathelicidins - [156]
PDS Targeting vRNA - §
PhenDC3 Targeting vRNA - §

Abbreviations: nrp—no result posted; cwr—completed with result; w—withdrawn; * no publication related to Enteroviruses available. Clinical trial repositories: ClinicalTrial.gov, accessed on 1 September 2021 and ClinicalTrialsRegister.eu, accessed on 1 September 2021. § unreviewed manuscript preprint [157].